Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...

Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl ...

FDA OKs New Wearable Infusion Device for Parkinson’sThe FDA has approved Onapgo, a new wearable device for adults with advanced Parkinson’s disease that gives a steady dose of apomorphine ...

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer. In a large cohort of ...

1 “ONAPGO represents a novel approach for adults with Parkinson’s disease who are experiencing motor fluctuations,” said Jack Khattar, President and CEO of Supernus Pharmaceuticals.

Supernus Pharmaceuticals’ Onapgo provides a continuous infusion of apomorphine to manage “off” periods experienced by Parkinson’s disease patients. Approval of Onapgo comes after the FDA ...

“In 2025, we look forward to continued Qelbree growth; the launch of ONAPGO for the treatment of Parkinson’s disease, planned for the second quarter of 2025; and further advancement of our ...

“In 2025, we look forward to continued Qelbree growth; the launch of ONAPGO for the treatment of Parkinson’s disease, planned for the second quarter of 2025; and further advancement of our ...

Supernus also announced FDA approval for ONAPGO, its treatment for motor fluctuations in adults with advanced Parkinson’s disease. The company plans to launch ONAPGO in the second quarter of 2025.